公开(公告)号：US20140163052A1

公开(公告)日：2014-06-12

申请号：US14088796

申请日：2013-11-25

Applicant: AMGEN INC.

Inventor： Xiaoqi Chen ,  Kang Dai ,  Jason Duquette ,  Michael W. Gribble, JR. ,  Justin N. Huard ,  Kathleen S. Keegan ,  Zhihong Li ,  Sarah E. Lively ,  Lawrence R. McGee ,  Mark L. Ragains ,  Xianghong Wang ,  Margaret F. Weidner ,  Jian Zhang

IPC: C07D471/14

CPC classification number: C07D519/00 ,  C07D471/14

Abstract: Compounds of Formula I are useful inhibitors of CDK 4, CDK6, and FLT3. Such compounds are useful in treating cancer and various other disease conditions. Compounds of Formula I have the following structure: where R1 is a group of Formula IA, Formula IB, Formula IC, or Formula ID and the definitions of the other variables are provided herein.

Abstract translation: 式I化合物是CDK 4，CDK 6和FLT 3的有用抑制剂。 这些化合物可用于治疗癌症和各种其他疾病状况。 式I的化合物具有以下结构：其中R1是式IA，式IB，式IC或式ID的基团，并且本文提供了其它变量的定义。

公开(公告)号：US20190062276A1

公开(公告)日：2019-02-28

申请号：US15927426

申请日：2018-03-21

Applicant: Amgen Inc.

Inventor： Michael D. Bartberger ,  Ana Gonzalez Buenrostro ,  Hilary Plake Beck ,  Xiaoqi Chen ,  Richard Victor Connors ,  Jeffrey Deignan ,  Jason A. Duquette ,  John Eksterowicz ,  Benjamin Fisher ,  Brian M. Fox ,  Jiasheng Fu ,  Zice Fu ,  Felix Gonzalez Lopez De Turiso ,  Michael W. Gribble, JR. ,  Darin J. Gustin ,  Julie A. Heath ,  Xin Huang ,  XianYun Jiao ,  Michael G. Johnson ,  Frank Kayser ,  David John Kopecky ,  SuJen Lai ,  Yihong Li ,  Zhihong Li ,  Jiwen Liu ,  Jonathan D. Low ,  Brian S. Lucas ,  Zhihua Ma ,  Lawrence R. McGee ,  Joel McIntosh ,  Dustin L. McMinn ,  Julio C. Medina ,  Jeffrey Thomas Mihalic ,  Steven H. Olson ,  Yosup Rew ,  Philip M. Roveto ,  Daqing Sun ,  Xiaodong Wang ,  Yingcai Wang ,  Xuelei Yan ,  Ming Yu ,  Jiang Zhu

IPC: C07D211/76 ,  C07D279/02 ,  C07D405/12 ,  C07D405/04 ,  C07D491/153 ,  C07D407/04 ,  C07D401/12 ,  C07D401/06 ,  C07D417/06 ,  C07D413/06 ,  C07D491/08 ,  C07D401/04 ,  C07D471/10 ,  C07D221/20 ,  C07D417/14 ,  C07D498/08 ,  C07D409/04 ,  C07D407/06 ,  C07D417/12 ,  C07D498/14 ,  C07D409/12 ,  C07D498/20

Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.